FDA letter and a recall target compounded GLP-1 drugs

Two FDA records from fall 2026 involve compounded GLP-1 products ^{[1, 2]}.

Warning letter to Empower Pharmacy

On September 18, 2026, FDA issued a warning letter to Empower Clinic Services, doing business as Empower Pharmacy ^[1]. FDA says its investigators collected evidence that the firm compounded products that were essentially copies of commercially available drugs, regularly and in inordinate amounts, including tirzepatide products ^[1].

Apothecary Pharma recall

Apothecary Pharma recalled 22 vials of compounded tirzepatide injection and 1 vial of NAD+ injection, distributed nationwide, for lack of assurance of sterility ^[2]. FDA lists it as a Class II recall that began on September 24, 2026 ^[2].

Peptides in this update

• Tirzepatide: FDA status, research and uses
• Semaglutide: FDA status, research and uses

More news

• DEA telemedicine flexibilities run through 2026
• FDA advisers review seven peptides for compounding
• FDA proposes keeping GLP-1s off the 503B bulks list
• FDA tells Lilly retatrutide is a drug, not a biologic
• FDA warns 30 telehealth firms over compounded GLP-1 ads
• HHS interim policy covers 6 peptides for compounding
• House bill would have the VA study peptide therapies
• Most peptides leave FDA's Category 2 list

Status of every peptide

• FDA Peptide Status Tracker

Sources

1. FDA: Warning letter, Empower Clinic Services dba Empower Pharmacy (Sep 18, 2026)
2. FDA: Enforcement report, Apothecary Pharma recall, event 99952

Updated November 5, 2026. Educational information, not medical advice.